Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/37981
Title: Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
Authors: 
Keywords: 
Mesh: 
Issue Date: 2018
Citation: BMC Cancer.2018 01;(18)1:106
Abstract: Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is lacking and the optimal EGFR TKI to be used remains unclear. This study aims to assess the real-life diagnostic and clinical management and outcome of patients with advanced non-small-cell lung cancer (NSCLC) carrying EGFR mutations in Spain.
PMID: 29382302
URI: https://hdl.handle.net/20.500.12530/37981
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. La Princesa > Artículos

Files in This Item:
File Description SizeFormat 
PMC5791371.pdf666.78 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.